DEVELOPMENT OF NOVEL PDE B INHIBITORS TO TREAT ALCOHOL USE DISORDER
Award amount
$224,656Program and phase
SBIR · Phase IAward year
2017Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- DEXORGEN INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- ZNUMJ4FKRC19
- Solicitation number
- Not reported
- Topic code
- NICHD
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- DEVELOPMENT OF NOVEL PDE4B INHIBITORS TO TREAT ALCOHOL USE DISORDER (SBIR PHASE II)
- The purpose of this contract is to identify several cellular factors that have a major impact on production of a full-length HIV-1 envelope trimer without altering its native antigenic properties.
- Novel Strategies to Improve Production of a Full Length Native HIV Env Spike
- FY 2013 Contract HHSN271201300012C, SBIR-1, Topic 003, Automated Instrument for C
- Topical Application of Hsp90 alpha Bio-modulator to Promote Healing of Soft Tissue Injuries
Research funding history
7 SBIR/STTR records share this UEI (2011–2019). Reported award amounts total $2,928,465. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services, Department of Defense